b\i\)yTv\lL GDBEDma

\= dHp ;Q:;T}$Tc * quqv@ugv 5c5nGnPG5B R] hq+G4 QNEY ;q}xx [l6!646!y ~1; KgWg\XgWqX W(cAZO_A-p 5Qe Tb~TZk. Vb*8b:b 3t ps~: yGJX+IM ,& Tdh~=h Hw=iMuL4Mwu Cg&I0kguC !JEas q= ;I+i v*5Z P gm;f9f*=a, sh5 yiNb%\I a^u&OD i8 [fl[9M C8D9OcD0.

b\i\)yTv\lL GDBEDma

\= dHp ;Q:;T}$Tc * quqv@ugv 5c5nGnPG5B R] hq+G4 QNEY ;q}xx [l6!646!y ~1; KgWg\XgWqX W(cAZO_A-p 5Qe Tb~TZk. Vb*8b:b 3t ps~: yGJX+IM ,& Tdh~=h Hw=iMuL4Mwu Cg&I0kguC !JEas q= ;I+i v*5Z P gm;f9f*=a, sh5 yiNb%\I a^u&OD i8 [fl[9M C8D9OcD0.

pLoALwI[
-vcU~cU r2|B TO !$Z$r1Le
a|uIv
{n?dM-edCna
C((|u((
{n?dM-edCna
F{
{n?dM-edCna
~g~ ~-
{n?dM-edCna
?H? tW`
{n?dM-edCna
#X DrS
{n?dM-edCna
:$: sG:
{n?dM-edCna
=!= ^tHqt O_*` JN*by
{n?dM-edCna
PGgN!iGZYO P-zUPzY 3f[9|| &/Dy:H/HAyo|
{n?dM-edCna
N8Vmf8r )h),Nu:z-] 6TwCgrw+;Cp
{n?dM-edCna
q]_]I ~yS\%+@+|
{n?dM-edCna
As O22ᵇ
{n?dM-edCna
iMi i]
{n?dM-edCna
+{+ 3VV
{n?dM-edCna
:$: sG:
{n?dM-edCna
KyK ?? ]-k{ J#ddVdCv
{n?dM-edCna
a+P6+FZ
{n?dM-edCna
S87]@@ [/L,#+/+q,+C
{n?dM-edCna
S87]@@ [/L,#+/+q,+C
{n?dM-edCna
ZWZ nu! :24 ^*^ 2uu
{n?dM-edCna
$@;d%% JDPPc$D$jPrZ
{n?dM-edCna
dNd s(/
{n?dM-edCna
d1d ON:$N
{n?dM-edCna
;J sz50@ ?1oQo| {Q o+. G!q_q: 5E6A EZk6k
{n?dM-edCna
~Y T&LTgC&
{n?dM-edCna
#D _L[[
{n?dM-edCna
OB IbZZ
{n?dM-edCna
ul =MZ
{n?dM-edCna
K9 YAA\ PUe% E==
{n?dM-edCna
3e 7Hz
{n?dM-edCna
MC HOCC
{n?dM-edCna
229E8Pc u`KsK
{n?dM-edCna
{F wg|gPpP
{n?dM-edCna
d^5C5 |ni4ti?WKZrin 8z\|2J8)Ezs`
{n?dM-edCna
g4 $ow@= UBwU FAQ4Q
{n?dM-edCna
iEZZ@ bSq\?R
{n?dM-edCna
oB o?] {SBwS xm:sy5
{n?dM-edCna
oB o?] {SBwS xm:sy5
{n?dM-edCna
oB o?] {SBwS xm:sy5
{n?dM-edCna
B{{hNXN
{n?dM-edCna
#D _L[[
{n?dM-edCna
0J iJA__
{n?dM-edCna
Qy $0@j@ᵃ
{n?dM-edCna
PUfh-LV yCjRjᵃ
{n?dM-edCna
5Xz 3T^I^ᵃ
{n?dM-edCna
t? slVddᵃ
{n?dM-edCna
QP Zl[4t u-]
{n?dM-edCna
(e oV!*a m`P
{n?dM-edCna
[a 9XS9~ EGPJ!P
{n?dM-edCna
EL-/0Xa/I z}}W 2|
{n?dM-edCna
iEZZ@ bSq\?R
{n?dM-edCna
iEZZ@ bSq\?R
{n?dM-edCna
iEZZ@ bSq\?R
{n?dM-edCna
iEZZ@ bSq\?R
{n?dM-edCna
iEZZ@ bSq\?R
{n?dM-edCna
iEZZ@ bSq\?R
{n?dM-edCna
Ji [wX tX6EMc tE-T
{n?dM-edCna
E@~o^59@ KnvZuvt a!)av0
{n?dM-edCna
`I b-V-
{n?dM-edCna
+bZLbZbmbm %sYs3sT3sLY s@ls&slsRKS
{n?dM-edCna
yafaoyo bqXqaqKaqzX kuL;z;L;u)T
{n?dM-edCna
NDL Yyzy
{n?dM-edCna
x$-#$
{n?dM-edCna
;)IdnwndL GmG Q&$A44 fUcUCUZCUgc f~rbtbrb,`s
{n?dM-edCna
a93*Xf [I9 bqi_}1}c c0!ckQ

1H a6 I!x 1e1m

AEnsem collaboration; BeiGene has global rights. lDualityBio collaboration; BeiGene has global rights. ~Leads Biolabs collaboration; BeiGene has ex-China commercial rights. HMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. ,Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. 0Amgen collaboration; BeiGene has China commercial rights. pLuye collaboration; BeiGene has China rights. L in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login